B152 First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) vs. VAD as Induction Treatment Prior to High-dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)

✍ Scribed by Sonneveld, P; Eljarari, L; Salwender, H; Zweegman, S; Vellenga, E; Van Der Holt, B; Schmidt-Wolf, IGH; Bertsch, U; Schubert, J; Blau, IW; Jie, GSK; Beverloo, B; Jauch, A; Hose, D; Schaafsma, R; Kersten, MJ; Delforge, M; De Weerdt, O; Van Der Griend, R; Wijermans, PW; Martin, H; Van Der Velde, H; Lokhorst, HM; Goldschmidt, H

• Book ID: 118629439
• Publisher: CIG Media Group, LP.
• Year: 2009
• Tongue: English
• Weight: 116 KB
• Volume: 9
• Category: Article
• ISSN: 1557-9190
• DOI: 10.1016/s1557-9190(11)70667-9